Johnson & Johnson (JNJ) stock news
The latest Johnson & Johnson news and press releases. 5 news stories in the last 24 hours, 1.9 times its usual daily coverage. JNJ stock report · Market news
Latest news
- Stock Screening Made Simple: A Closer Look Zacks Investment Research, Nov 20, 2:11 AM UTC
Stock screening is commonly deployed by investors to 'cut through the noise.' The approach is especially useful when you're choosing from thousands of options, which can often overwhelm investors. - Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care The Motley Fool, Nov 19, 11:45 PM UTC
Johnson & Johnson's JNJ-6143 posted excellent results in an early-stage clinical trial. For income investors, the real story is a Dividend King with a deep lineup and pipeline. - 3 Dow Dividend Passive Income Stocks for Retirement, Led by a 64-Year Streak 24/7 Wall Street, Nov 19, 8:32 PM UTC
Before building a retirement paycheck, see which dividend is best covered, which stock looks stretched, and what risks hide beneath each yield. - How Retirees Can Turn $1 Million Into Passive Income With These 5 Dividend Stocks 247 Wallst, Nov 19, 6:00 PM UTC
A million dollars sounds like plenty until you need it to pay you every month. Five blue chips across five sectors split the load, but one of them carries far more weight than the rest, and that lopsidedness raises a ... - Want Steady Dividend Income? Invest in These 3 Dividend Kings With 64 Years of Raises 24/7 Wall Street, Nov 19, 1:33 PM UTC
Each of the three covers its payout with recurring cash flow, investment-grade discipline and decades of annual raises. - Want Reliable Retirement Income? Invest in These 3 Dow Jones Passive Income Dividend Stocks 24/7 Wall Street, Nov 19, 1:18 PM UTC
Retirement income holds up best when it comes from companies that have already kept paying through recessions, rate shocks, and bear markets. Coca-Cola (NYSE: KO | KO Price Prediction), Johnson & Johnson (NYSE: JNJ), ... - Invest $25,000 in These 4 Dividend Stocks to Start Building Retirement Income 24/7 Wall Street, Nov 18, 4:30 PM UTC
Retirement changes what a portfolio is for. Once the paycheck stops, the number that matters most is how much cash the account sends back each year without pushing a sale of shares. - Here's How Much Passive Income $50,000 Generates in These 4 Dividend Aristocrats 24/7 Wall Street, Nov 18, 2:02 PM UTC
Four household-name stocks have raised their dividends for 40 to 70 straight years, yet each one carries a risk that could threaten the streak. Which payout looks safest, and which check is biggest? - Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? The Motley Fool, Nov 17, 11:27 PM UTC
Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while ex... - 2 of the Best Dividend Stocks to Buy With $5,000 in November Fool - Investing News, Nov 17, 11:26 PM UTC
These two dividend stocks offer reliable raises year after year. - Johnson & Johnson vs. Pfizer: Consistency vs. The Motley Fool, Nov 17, 6:30 PM UTC
Johnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period. Over roughly the last eight quarters, Johnson ... - J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts Zacks Investment Research, Nov 17, 4:46 PM UTC
J&J's $2.2 billion Ollin Biosciences deal adds a promising retinal disease candidate, building on acquisitions. - J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition Zacks Investment Research, Nov 17, 4:26 PM UTC
JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development. - Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead 24/7 Wall Street, Nov 17, 2:15 PM UTC
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) grounds countless retirement portfolios. SCHD screens for durable dividend payers, holds $112.3 billion in net assets and pays a trailing yield near 2.94%. - 3 Bulletproof Passive Income Dividend Kings to Buy and Hold Forever 24/7 Wall Street, Nov 17, 1:31 PM UTC
A pending IRS ruling, rising commodity costs, and more test whether the payouts of these passive income Dividend Kings can survive. - Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. The Motley Fool, Nov 17, 11:25 AM UTC
Johnson & Johnson currently exhibits a stronger overall position by generating a substantially larger total revenue volume than Novo Nordisk. Johnson & Johnson maintained a consistent quarter-over-quarter upward traje... - Johnson & Johnson (NYSE:JNJ) Stock Falls 1.1% After Insider Selling Defense World, Nov 17, 6:45 AM UTC
Shares of Johnson and Johnson (NYSE: JNJ - Get Free Report) dropped 1.1% on Monday following insider selling activity. The stock traded as low as $282.33 and last traded at $282.6220. Approximately 7,837,458 shares tr... - J&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold? Zacks Investment Research, Nov 16, 4:36 PM UTC
JNJ's rally reflects stronger earnings and promising drug launches, but MedTech weakness, patent losses and litigation risks remain. - Treasury Yields Just Hit 4.88%, Changing the Math for Dividend Investors 247 Wallst, Nov 16, 4:17 PM UTC
A short-term bond fund and a 64-year dividend streak both promise income, but one can shrink when the Fed moves and the other can fall harder in a bad year. Taxes may decide which one actually pays you more. - Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology GuruFocus, Nov 16, 2:00 PM UTC
Johnson and Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (âOllinâ) a clinical-stage biop - Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion WSJ, Nov 16, 1:37 PM UTC
Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases. - BTAL Buys the Market’s Calmest Stocks and Shorts Its Wildest. It Is Built to Rise When Stocks Fall 247 Wallst, Nov 16, 1:03 PM UTC
One little-known fund bets against the market's wildest stocks and can cushion a retiree's portfolio when a selloff hits. But the same design has quietly cost holders during every long rally, and the tradeoff is worth... - 4 Durable Dividend Stocks Retirees Can Count On for Passive Income 247 Wallst, Nov 15, 3:00 PM UTC
One company has raised its dividend through seven decades of recessions, yet it is not the only name retirees should trust. Each of these four payers faces a real risk that could test the check, and the safest one may... - Johnson & Johnson $JNJ Shares Newly Purchased by AlpenGlobal Capital LLC Defense World, Nov 14, 9:41 AM UTC
AlpenGlobal Capital LLC acquired a new stake in Johnson and Johnson (NYSE: JNJ) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm ... - 4 Healthcare Dividend Stocks for Retirees. One Yields Over 4% 247 Wallst, Nov 13, 8:47 PM UTC
A fat starting yield can hide thin raises, while the slowest payers boast decades of increases. Four low-volatility healthcare blue chips force retirees to choose between income today and income that grows, and the ga... - 4 Dividend Kings That Kept Raising Payouts Through Recessions and High Interest Rates 247 Wallst, Nov 13, 4:17 PM UTC
Four Dividend Kings raised payouts through a financial crisis, zero rates, and the sharpest hikes in decades. Only one yields above 5%, and its thin cash flow makes the next raise the one to watch. - I Bonds Pay 5.51%. Here’s What Dividend Investors Should Know 247 Wallst, Nov 13, 2:47 PM UTC
A government-backed bond now out-yields one of the most reliable dividend payers on the market, but the headline number hides a one-year lockup, a rate that resets, and a tax twist. Which income stream really keeps mo... - 5 Dividend Aristocrats and Kings to Consider if the Stock Market Sells Off 247 Wallst, Nov 13, 1:11 PM UTC
Market indicators are flashing red heading into October, and investors who wait too long to reposition may regret it. Five elite dividend stocks in healthcare, consumer staples, and utilities have weathered every majo... - How Much Does a 69-Year-Old Need Invested in Dividend Stocks to Collect $3,000 a Month? 247 Wallst, Nov 13, 12:32 PM UTC
The price tag for $3,000 a month in dividends swings by more than a million dollars depending on which stocks you pick. One popular income pick looks cheapest to start and may cost the most by age 79. - The Big 3: JNJ, LLY, AAPL Schwab Network, Nov 12, 6:00 PM UTC
Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks including Johnson ...
Press releases
- Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System Business Wire, Nov 19, 1:51 PM UTC
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that Memorial Hermann-Texas Medical Center in Houston, Texas will be the first hospital to install the OTTAVA™ Robotic Surgical System, represent... - Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication PRNewsWire, Nov 19, 1:01 PM UTC
Two positive Phase 3 studies showed CAPLYTA significantly reduced manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 As the first and only FDA-approved treatment for both bipola... - Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson Business Wire, Nov 17, 5:14 PM UTC
DALLAS--(BUSINESS WIRE)--An appeals court in Louisiana has upheld a multimillion verdict against Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's mesothelioma and dea... - Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology Business Wire, Nov 16, 1:00 PM UTC
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage biopharmaceutical company d... - Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case Business Wire, Nov 11, 4:36 PM UTC
DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a verdict in the amount of $1,914,990 accompanied by court ordered interest of $1,410,541 for a sum total of $... - Dean Omar Branham Shirley Secures $3,325,000 Verdict Against Johnson & Johnson in Mesothelioma Case Business Wire, Nov 10, 2:00 PM UTC
DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a $3,325,000 jury verdict against Johnson & Johnson on behalf of the family of Winifred “Missy” Haddad, a Mass... - Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study PRNewsWire, Nov 10, 1:00 PM UTC
CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studies Two positive Phase 3 studies will support... - Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer PRNewsWire, Nov 8, 4:00 PM UTC
First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer Deep and su... - Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients PRNewsWire, Nov 7, 3:03 PM UTC
New patient experience data a to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 s... - Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide PRNewsWire, Nov 7, 3:03 PM UTC
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at... - Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer PRNewsWire, Nov 6, 2:03 AM UTC
Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 First advancement in the second-line trea... - Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results Business Wire, Nov 1, 1:00 PM UTC
SAN DIEGO--(BUSINESS WIRE)-- #PressRelease--Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) ...
Headlines link to their publishers. Research data, not investment advice.